AstraZeneca (AZN) Receives Buy Rating from BMO Capital Markets

BMO Capital Markets restated their buy rating on shares of AstraZeneca (NYSE:AZN) in a research report released on Friday morning. They currently have a $41.00 target price on the stock.

A number of other equities research analysts have also recently commented on AZN. ValuEngine upgraded AstraZeneca from a buy rating to a strong-buy rating in a research note on Saturday, February 3rd. Sanford C. Bernstein lifted their target price on AstraZeneca from $40.00 to $42.00 and gave the stock an outperform rating in a research note on Monday, February 5th. Leerink Swann lifted their target price on AstraZeneca from $36.00 to $38.00 and gave the stock a market perform rating in a research note on Tuesday, February 6th. Jefferies Group upgraded AstraZeneca from a hold rating to a buy rating and lifted their target price for the stock from $28.43 to $36.70 in a research note on Monday, March 19th. Finally, Zacks Investment Research upgraded AstraZeneca from a sell rating to a hold rating in a research note on Tuesday, March 20th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $38.28.

AstraZeneca opened at $37.04 on Friday, according to MarketBeat Ratings. The company has a current ratio of 0.73, a quick ratio of 0.62 and a debt-to-equity ratio of 1.08. The firm has a market cap of $93.41 billion, a price-to-earnings ratio of 8.65, a PEG ratio of 1.95 and a beta of 0.61. AstraZeneca has a 1 year low of $28.43 and a 1 year high of $37.30.

AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Friday, May 18th. The company reported $0.48 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.28 by $0.20. The firm had revenue of $5.18 billion for the quarter, compared to the consensus estimate of $5.24 billion. AstraZeneca had a net margin of 12.61% and a return on equity of 30.73%. The business’s revenue for the quarter was down 4.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.99 EPS. analysts expect that AstraZeneca will post 1.7 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the stock. Summit Trail Advisors LLC raised its stake in AstraZeneca by 8.4% in the 1st quarter. Summit Trail Advisors LLC now owns 17,691 shares of the company’s stock valued at $302,000 after acquiring an additional 1,371 shares during the period. Commerce Bank increased its position in shares of AstraZeneca by 14.7% during the fourth quarter. Commerce Bank now owns 11,548 shares of the company’s stock valued at $400,000 after buying an additional 1,480 shares during the period. M&T Bank Corp increased its position in shares of AstraZeneca by 0.5% during the fourth quarter. M&T Bank Corp now owns 317,119 shares of the company’s stock valued at $11,003,000 after buying an additional 1,676 shares during the period. TIAA FSB increased its position in shares of AstraZeneca by 6.7% during the fourth quarter. TIAA FSB now owns 27,087 shares of the company’s stock valued at $940,000 after buying an additional 1,692 shares during the period. Finally, First Allied Advisory Services Inc. increased its position in shares of AstraZeneca by 7.6% during the fourth quarter. First Allied Advisory Services Inc. now owns 23,845 shares of the company’s stock valued at $825,000 after buying an additional 1,694 shares during the period. Institutional investors and hedge funds own 15.59% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Analyst Recommendations for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply